

- Pharmacol. Biochem. Behav.* **6**, 615 (1977); D. C. S. Roberts, G. F. Koob, P. Klonoff, H. C. Fibiger, *ibid.* **12**, 781 (1980).
3. J. R. Bunzow *et al.*, *Nature* **336**, 783 (1988); A. Deary *et al.*, *ibid.* **347**, 72 (1990); F. J. Monsma, L. C. Mahan, L. D. McVittie, C. R. Gerfen, D. R. Sibley, *Proc. Natl. Acad. Sci. U.S.A.* **87**, 6723 (1990).
 4. P. Sokoloff, B. Giros, M.-P. Martres, M. L. Bouthenet, J. C. Schwartz, *Nature* **347**, 146 (1990).
 5. R. K. Sunahara *et al.*, *ibid.*, p. 80; R. K. Sunahara *et al.*, *ibid.* **350**, 614 (1991); M. Tiberi *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* **88**, 7491 (1991).
 6. With the currently available selective ligands, both D-1 and D-2 receptor subtypes have been implicated in the reinforcing properties of cocaine [G. F. Koob, H. T. Le, I. Creese, *Neurosci. Lett.* **79**, 315 (1987); J. Bergman, J. B. Kamien, R. D. Spealman, *Behav. Pharmacol.* **1**, 355 (1990); D. R. Britton *et al.*, *Pharmacol. Biochem. Behav.* **39**, 911 (1991); C. B. Hubner and J. E. Moreton, *Psychopharmacology Berlin* **105**, 151 (1991)].
 7. D. Levesque *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* **89**, 8155 (1992).
 8. J. C. Schwartz, B. Giros, M.-P. Martres, P. Sokoloff, *Semin. Neurosci.* **4**, 99 (1992).
 9. Each infusion contained 0.25 mg of cocaine in a volume of 100 μ l of saline. Baseline rates were defined as three consecutive sessions with less than 10% variation in the total number of self-injections. Various doses of dopamine agonists were combined with cocaine according to a Latin-square design to randomize the order of doses. Other details as previously described [S. B. Caine, R. Lintz, G. F. Koob, in *Behavioral Neuroscience: A Practical Approach*, A. Sahgal, Ed. (Oxford Univ. Press, Oxford, in press)].
 10. Drug self-administration in animals exhibits a characteristic inverted U-shaped dose-response curve, and manipulations that shift this curve to the left can be interpreted as increasing the reinforcing potency of the drug. Pretreatments with dopamine agonists before the session have been shown to produce this effect by decreasing the frequency of cocaine self-injections [C. B. Hubner and G. F. Koob, *Neuropsychopharmacology* **3**, 101 (1990)]. Alternatively, this effect can be interpreted as enhancing the rate-decreasing effects of cocaine [S. Herling, D. A. Downs, J. H. Woods, *Psychopharmacology Berlin* **64**, 261 (1979)].
 11. Relative potency is the ratio of the amounts of each drug needed to produce the specified effect; a higher numerical value indicates a weaker relative potency. The relative potencies of the agonists to decrease cocaine self-administration were calculated from comparisons of the dose (micromoles) response; 7-OHDPAT was assigned unit potency (1.0). The relative potencies were 3.22 for quinpirole and 8.97 for apomorphine (the correlation coefficients of the regression lines for the potency estimates were $r = 0.79$, $r = 0.85$, and $r = 0.88$, respectively) [R. J. Tallarida and R. B. Murray, *Manual of Pharmacologic Calculations with Computer Programs* (Springer-Verlag, New York, 1987), pp. 35–38].
 12. The regression analysis indicated a significant correlation of $r = 0.99$ [$F(1,2) = 414.4$, $P < 0.05$].
 13. The regression analyses indicated no significant positive correlation between the relative potencies of the three agonists to decrease cocaine self-administration and their K_i values for the D-2, D-1, or D-4 receptor. Indeed, the correlation coefficients for the regression lines were negative ($r = -0.31$, $r = -0.68$, and $r = -0.75$, respectively, $P > 0.1$ in each case).
 14. Low doses of the agonists were not sufficiently reinforcing to produce self-administration in two of the three animals tested with each drug (4 μ g of 7-OHDPAT: 2, 2, and 258 injections in 3 hours; 4 μ g of quinpirole: 2, 2, and 164 injections in 3 hours; and 8 μ g of apomorphine: 0, 11, and 58 injections in 3 hours), but as the dose was increased, characteristic patterns of self-administration were produced in all animals such that the dose per injection was inversely related to the total number of self-injections.
 15. W. M. Davis and S. G. Smith, *Life Sci.* **20**, 483 (1977).
 16. C. A. Gill, W. C. Holz, C. L. Zirkle, H. Hill, in *Proceedings of the 10th Congress of the Collegium Internationale Neuro-Psycho-pharmacologicum*, P. Denicker, C. Radouco-Thomas, A. Villeneuve, Eds. (Pergamon, New York, 1978), pp. 1477–1484; W. L. Woolverton, L. I. Goldberg, J. Z. Ginos, *J. Pharmacol. Exp. Ther.* **230**, 678 (1984); J. Bergman and R. D. Spealman, *FASEB J.* **2**, A1137 (1988).
 17. Total number of self-injections in 3 hours (mean \pm SEM, $n = 3$, same subjects): cocaine (0.25 mg) alone, 37.4 ± 3.5 ; apomorphine (16 μ g) in combination with cocaine (0.25 mg), 21.2 ± 0.8 ; apomorphine (32 μ g) alone, 21.4 ± 0.7 . A double dose of cocaine (0.5 mg) has been shown to reduce the total number of cocaine self-injections by about half [G. F. Koob, F. J. Vaccarino, M. Amalric, F. E. Bloom, in *Brain Reward Systems and Abuse*, J. Engel and L. Oreland, Eds. (Raven, New York, 1987), pp. 35–50].
 18. As in (17): cocaine (0.25 mg) alone, 46.8 ± 3.0 ; 7-OHDPAT (4 μ g) in combination with cocaine (0.25 mg), 24.0 ± 2.4 ; 7-OHDPAT (128 μ g) alone, 45.0 ± 6.5 .
 19. As in (17): cocaine (0.25 mg) alone, 43.4 ± 0.8 ; quinpirole (4 μ g) in combination with cocaine (0.25 mg), 23.2 ± 1.9 ; and quinpirole (128 μ g) alone, 48.3 ± 16.8 .
 20. $F(3,15) = 1.1$, $P > 0.1$, main effect, analysis of variance (ANOVA) ($n = 5$).
 21. K. Svennson, A. M. Johansson, T. Magnusson, A. Carlsson, *Naunyn Schmiedeberg Arch. Pharmacol.* **334**, 234 (1986); M. E. Wolf and R. H. Roth, in *Dopamine Receptors*, I. Creese and C. M. Frazer, Eds. (Liss, New York, 1987), vol. 8, p. 45.
 22. S. B. Caine, M. F. Piercey, G. F. Koob, unpublished data.
 23. P. M. Callahan, M. F. Piercey, K. A. Cunningham, *Psychopharmacology Berlin* **107**, 73 (1992).
 24. I. Creese and S. D. Iversen, *Brain Res.* **83**, 419 (1975); P. H. Kelly, P. W. Seviour, S. D. Iversen, *ibid.* **94**, 507 (1975).
 25. J. M. Cedarbaum and L. S. Schleifer, in *The Pharmacological Basis of Therapeutics*, A. G. Gilman *et al.*, Eds. (Pergamon, New York, 1990), p. 470.
 26. F. H. Gawin, *Science* **251**, 1580 (1991).
 27. All studies were performed within-subject and analyzed by overall one-way repeated measures ANOVA [7-OHDPAT, $F(4,28) = 24.5$; quinpirole, $F(6,30) = 20.1$; apomorphine, $F(5,25) = 36.9$; for each, $P < 0.0001$].
 28. We thank R. Amstutz, D. Römer, E. Rissi, and P. Seiller of Sandoz Inc., Basel, Switzerland, for providing 7-OHDPAT. We also thank F. E. Bloom for comments throughout these studies and B. Everitt, L. Gold, G. Schulteis, A. Markou, and B. Baldo for comments on the manuscript. Supported by National Institute on Drug Abuse (NIDA) grant DA04398 to G.F.K. and NIDA predoctoral fellowship DA05478 to S.B.C. All animal procedures conformed to the *Guide for the Care and Use of Laboratory Animals* endorsed by the National Institutes of Health. This is publication 7732-NP from The Scripps Research Institute.

7 December 1992; accepted 9 March 1993

Molecular Cloning of an Apolipoprotein B Messenger RNA Editing Protein

BaBie Teng, Charles F. Burant, Nicholas O. Davidson*

Mammalian apolipoprotein B (apo B) exists in two forms, each the product of a single gene. The shorter form, apo B48, arises by posttranscriptional RNA editing whereby cytidine deamination produces a UAA termination codon. A full-length complementary DNA clone encoding an apo B messenger RNA editing protein (REPR) was isolated from rat small intestine. The 229-residue protein contains consensus phosphorylation sites and leucine zipper domains. HepG2 cell extracts acquire editing activity when mixed with REPR from oocyte extracts. REPR is essential for apo B messenger RNA editing, and the isolation and characterization of REPR may lead to the identification of other eukaryotic RNA editing proteins.

Apolipoprotein B is a critical structural component of circulating lipoproteins and a major etiologic factor in atherosclerosis susceptibility (1). The liver synthesizes a 550-kD form of apo B, apo B100, whereas a smaller form, apo B48, is produced from the small intestine by posttranscriptional editing of a CAA (glutamine) to a UAA (stop) codon in apo B mRNA (2, 3). The truncated apo B48 protein lacks the receptor-binding domains for low-density lipoprotein present in apo B100 and is therefore catabolized by a different receptor pathway (4, 5). Intestinal apo B mRNA editing is developmentally regulated in humans and other mammals (6–8) and

appears to be mediated by a protein factor or factors that are sequence-, tissue-, and species-specific (9–18).

We developed a functional complementation assay for apo B RNA editing on the basis of our recent observation (18) that chicken enterocyte S100 extracts enhance in vitro editing of mammalian apo B RNA (Fig. 1) in spite of the fact that chicken apo B mRNA is not itself edited. Rat intestinal polyadenylated [poly(A)⁺] RNA was size-fractionated by sucrose gradient ultracentrifugation (19) and injected into *Xenopus* oocytes. One fraction (fraction 4, Fig. 1) yielded editing activity in oocyte extracts, a function dependent on the addition of chicken enterocyte S100 extract. This functionally active mRNA fraction was used to construct a plasmid cDNA library that contained $\sim 1 \times 10^6$ cDNA clones. Screening

Department of Medicine, University of Chicago, MC 4076, Chicago, IL 60637.

*To whom correspondence should be addressed.

was carried out with the use of sib selection (20), which led to the isolation of a single positive clone (131) designated apo B mRNA editing protein (REPR). In the presence of chicken enterocyte S100 extracts, oocyte homogenates expressing this protein edit more than 50% of a synthetic rat apo B RNA template (Fig. 1).

The DNA and deduced amino acid sequence of REPR are shown in Fig. 2A. The nucleotide sequence is 833 base pairs (bp) long and contains a polyadenylate tract of more than 100 bases. The single open reading frame encodes a 229-amino

acid protein with a calculated molecular mass of 27,277 daltons. A search of the National Center for Biotechnology Information peptide sequence database (release 73.1) did not show any other proteins with significant sequence similarity. REPR contains consensus phosphorylation sites for cyclic AMP-dependent kinase (residue 33), protein kinase C (residues 13, 58, and 72), and casein kinase (residue 145). Two leucine zipper motifs were also identified at residues 182 to 203 and residues 189 to 210.

A 1.0-kb transcript encoding REPR is present at highest abundance in RNA from

rat small intestine and at lower levels in colon, whereas a 1.24-kb transcript is found at high levels in liver and at lower abundance in kidney, spleen, and lung (Fig. 2B). No hybridization signal was found in brain, heart, stomach, or testis.

Oocyte extracts expressing REPR edit apo B mRNA only in the presence of either chicken (Figs. 1 and 3) or rat intestinal S100 extract (21), suggesting an interaction of REPR with another factor or factors. Additionally, a synthetic rat apo B RNA template was not edited after coinjection with REPR into oocytes (21). Recent estimates of the size of proteins involved in apo B RNA editing range from 40 to 125 kD, suggesting that REPR may be a component of a larger complex that may include specific apo B RNA binding proteins (10, 14, 22). However, no protein of the anticipated size of REPR was identified among several apo B mRNA binding proteins recently reported (22). We investigated the importance of the leucine zipper domains in REPR in mediating interactions with another factor or factors because this motif has been postulated to stabilize the interaction of homo- and heterodimeric protein complexes (23). Linearization at a Sty I site located at nucleotide 543, upstream of the leucine zipper domains, yielded an in vitro translation product with an apparent molecular mass of 20 kD, as opposed to 25 kD for the full-length translation product (Fig. 3A). This elimination of the leucine

Fig. 1. Expression cloning of apo B mRNA editing protein. In vitro RNA editing assays were done with S100 extracts prepared from rat or chicken enterocytes (27), demonstrating cooperative interaction as determined by primer extension analysis (control). *Xenopus* oocytes injected (28) with H₂O or 100 ng of size-fractionated rat intestinal poly(A)⁺ RNA

(19) demonstrate a single fraction (number 4) with in vitro editing activity in the presence of chicken intestinal S100 extract. This RNA fraction was used for cDNA library construction. Functional screening with sib selection (20) yielded a single positive clone (number 131). Synthetic RNA (100 ng) transcribed from this clone produced over 50% editing of synthetic rat apo B RNA when assayed in the presence of chicken intestinal S100 extract.






Fig. 2. Sequence and tissue distribution of REPR. (A) Nucleotide and predicted amino acid sequence of REPR. The Sty I site used to generate the truncated REPR is underlined, as are the two leucine zipper domains. The cDNA sequence has been deposited with GenBank (accession number L07114). (B) Tissue distribution of REPR mRNA. We prepared Northern (RNA) blots by using either 20 μ g of total RNA from adult rat tissues

[B, brain; H, heart; L, lung; St, stomach; Li, liver; Sp, spleen; K, kidney; C, colon; SI, small intestine; and T, testis] or 5 μ g of poly(A)⁺ RNA from liver and small intestine that were fractionated through 1% agarose-6% formaldehyde gels before capillary transfer and high-stringency hybridization (18) with a 422-bp Sma 1-Kpn 1 fragment of REPR (nucleotides 129 to 551). The autoradiogram was exposed at -80°C with two intensifying screens for 6 days. Ribosomal RNAs (28S and 18S) are indicated. The lower portion shows the ethidium bromide-stained gel of total RNA.

zipper domains from REPR completely abolished the editing activity (Fig. 3B) in oocyte extracts, suggesting that this region is necessary for the editing function of the protein.

We investigated the interaction of REPR with other sources of cytoplasmic S100 extract to provide insight into the cell-specific distribution of the apo B mRNA editing machinery. G-292 cells have previously been shown to edit a transfected, chimeric apo B-apo E RNA, although like CHO cells, they do not express endogenous apo B mRNA (11). S100 extracts were also prepared from HepG2 cells, in which apo B mRNA is unedited (3), and McA₇₇₇₇ cells, in which apo B mRNA is edited at a low level (9). At the concentra-

tions used, no editing activity was detectable with these S100 extracts either alone or together with chicken enterocyte S100 extracts (Fig. 4, left and middle). However, addition of REPR increased editing with HepG2 and McA₇₇₇₇ extracts to 23% and 30%, respectively, whereas G292 and CHO cell extracts failed to complement REPR activity (Fig. 4, right). The failure of G292 extracts to complement in vitro editing activity in spite of the ability of this cell to edit a transfected apo B-apo E chimera may be attributable either to structural differences in the apo B RNA template (24) or to the very low levels contained by (cytoplasmic) S100 extracts of the factor or factors responsible for editing of the (nuclear) transcript (25).

Fig. 3. Apo B mRNA editing protein activity is abolished after elimination of the leucine zipper domains. (A) In vitro translation analysis of full-length apo B mRNA editing protein (linearized with Not I) and a truncated apo B mRNA editing protein that lacks the leucine zipper domains (linearized with Sty I, Fig. 2A). Approximately 1 μ g of capped synthetic RNA was transcribed and translated with [³⁵S]methionine. The products were analyzed by 12.5% SDS-polyacrylamide gel electrophoresis and stained with Coomassie blue; the fluorogram is shown. Molecular size markers are indicated at left. (B) In vitro RNA editing assays demonstrate the requirement for additional factors for effective conversion by REPR (left and middle). REPR expressed in oocyte homogenates is ineffective in the absence of either chicken or rat (21) enterocyte S100 extract. The importance of the leucine zipper domains (right) is suggested by the abolition of in vitro apo B RNA editing with the Sty I truncated protein. In vitro editing assays were performed as in Fig. 1 and used similar amounts of oocyte homogenate.





Fig. 4. Interaction of S100 extracts prepared from G292, HepG2, CHO, and McA₇₇₇₇ cells with oocyte homogenates expressing REPR. Control in vitro editing reactions are shown, with conditions as described in Fig. 1. S100 extracts were prepared from G292, HepG2, CHO, and McA₇₇₇₇ cells and assayed alone (no addition) or with 10 μ g of chicken enterocyte S100 extracts (+ chick S100). In neither of these conditions was in vitro editing observed (<5%). In the presence of 10 μ g of oocyte homogenate expressing REPR (+ oocyte homogenate), effective in vitro conversion with both HepG2 and McA₇₇₇₇ extracts was observed. Apo B RNA editing was assayed by primer extension, and the primer, unedited (CAA), and edited (UAA) products are shown.



We have thus isolated and characterized a cDNA encoding a protein essential to intestinal apo B mRNA editing. This clone will facilitate the identification of other components of the apo B RNA editing machinery that appear to be widely distributed in human tissues (6). In addition, the clone may help identify other genes involved in sequence-specific RNA editing such as occurs in a differential manner among the brain glutamate receptor subunits (26).

REFERENCES AND NOTES

1. J. L. Breslow, *Physiol. Rev.* **68**, 85 (1988).
2. L. M. Powell *et al.*, *Cell* **50**, 831 (1987).
3. S.-H. Chen *et al.*, *Science* **238**, 363 (1987).
4. R. J. Pease *et al.*, *J. Biol. Chem.* **265**, 553 (1990).
5. J. Herz *et al.*, *EMBO J.* **7**, 4119 (1988).
6. B. Teng, M. Verp, J. Salomon, N. O. Davidson, *J. Biol. Chem.* **265**, 20616 (1990).
7. B. Teng, D. D. Black, N. O. Davidson, *Biochem. Biophys. Res. Commun.* **173**, 74 (1990).
8. J. H. Wu, C. F. Semenkovich, S.-H. Chen, W.-H. Li, L. Chan, *J. Biol. Chem.* **265**, 12312 (1990).
9. D. M. Driscoll, J. K. Wynne, S. C. Wallis, J. Scott, *Cell* **58**, 519 (1989).
10. P. P. Lau, S.-H. Chen, J. C. Wang, L. Chan, *Nucleic Acids Res.* **18**, 5817 (1990).
11. H. C. Smith *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* **88**, 1489 (1991).
12. P. E. Hodges, N. Navaratnam, J. C. Greeve, J. Scott, *Nucleic Acids Res.* **19**, 1197 (1991).
13. K. Bostrom *et al.*, *J. Biol. Chem.* **265**, 22446 (1990).
14. D. M. Driscoll and E. Casanova, *ibid.*, p. 21401.
15. S.-H. Chen, X. Li, W. S. L. Liao, W. J. H. Liao, L. Chan, *ibid.*, p. 6811.
16. R. R. Shah *et al.*, *ibid.* **266**, 16301 (1991).
17. Z. C. Garcia *et al.*, *Arteriosclerosis* **12**, 172 (1991).
18. B. Teng and N. O. Davidson, *J. Biol. Chem.* **267**, 21265 (1992).
19. K. Sumikawa, I. Parker, T. Amano, R. Miledi, *EMBO J.* **3**, 2291 (1984). Approximately 100 μ g of rat intestinal poly(A)⁺ RNA was fractionated by sucrose gradient ultracentrifugation. Fraction 4 was used to prepare a cDNA library with the Superscript Plasmid System (BRL).
20. M. McCormick, *Methods Enzymol.* **151**, 445 (1987).
21. B. Teng, C. F. Burant, N. O. Davidson, unpublished results.
22. N. Navaratnam, R. Shah, D. Patel, V. Fay, J. Scott, *Proc. Natl. Acad. Sci. U.S.A.* **90**, 222 (1993).
23. W. H. Landschulz, P. F. Johnson, S. L. McKnight, *Science* **240**, 1759 (1988).
24. J. W. Backus and H. C. Smith, *Nucleic Acids Res.* **19**, 6781 (1991).
25. P. P. Lau, W. Xiong, H.-J. Zhu, S.-H. Chen, L. Chan, *J. Biol. Chem.* **266**, 20550 (1991).
26. B. Sommer, M. Kohler, R. Sprengel, P. H. Seeburg, *Cell* **67**, 11 (1991).
27. Approximately 11 fmol of synthetic rat apo B RNA (pRBF-CAA) was incubated for 2 hours at 30°C with buffer only (-), 10 μ g of chick enterocyte S100 extract (+), 10 μ g of rat enterocyte S100 (+), or 10 μ g of oocyte homogenate (+). Apo B RNA was subsequently analyzed by primer extension. The position of primer, unedited (CAA), and edited products (UAA) are indicated.
28. T. Kayano *et al.*, *J. Biol. Chem.* **265**, 13276 (1990). Plasmid DNA was linearized with Not I and used for in vitro transcription and capping. RNA (1 μ g/ μ l) was dissolved in H₂O and injected into *Xenopus* oocytes, which were then incubated at 19°C for 48 hours and homogenized in Dignam buffer A containing freshly added protease inhibitors [T. D. Dignam, R. M. Lebovitz, R. G. Roeder, *Nucleic Acids Res.* **11**, 1475 (1983)]. After dialysis for 2 to 8 hours against Dignam buffer D, protein concentration was determined colorimetrically [M. Bradford, *Anal. Biochem.* **72**, 248 (1976)] and

the homogenate stored at -80°C .
 29. We thank M. Kwon, V. Trieu, D. K. Bonen, F. Giannoni, C. Hadjiagapiou, G. I. Bell, and A. D. Sniderman for helpful discussions. Supported by a grant-in-aid (to B.T.) from the American Heart

Association (Chicago affiliate) and awards HL-38180, KO-4 HL-02166, and DK-42086 (to N.O.D.) from NIH.

21 January 1993; accepted 19 April 1993

Rapid Remodeling of Axonal Arbores in the Visual Cortex

Antonella Antonini and Michael P. Stryker

If vision in one eye is blurred or occluded during a critical period in postnatal development, neurons in the visual cortex lose their responses to stimulation through that eye within a few days. Anatomical changes in the nerve terminals that provide input to the visual cortex have previously been observed only after weeks of deprivation, suggesting that synapses become physiologically ineffective before the branches on which they sit are withdrawn. Reconstruction of single geniculocortical axonal arbors in the cat after either brief or prolonged monocular occlusion revealed striking axonal rearrangements in both instances. Rapid withdrawal of the branches of deprived-eye arbors suggests that axonal branches bearing synapses respond quickly to changing patterns of neuronal activity.

During a critical period in early postnatal life neurons in the primary visual cortical area (area 17) of animals with binocular vision are particularly susceptible to an imbalance in the visual experience of the two eyes (1). In cat and monkey, monocular deprivation (MD), that is, depriving one eye of patterned vision by closing the eyelids (2–4) while allowing the other eye normal visual input, leads to physiological and anatomical changes in area 17.

In normal animals, the left and right eyes drive nearly equal numbers of cortical neurons, and the vast majority (>80%) of neurons are binocularly driven. The anatomical basis for this physiology is the division of the major input layer of cortex, layer 4, into nearly equal-sized patches innervated by the afferents that serve the two eyes. After MD, most neurons in area 17 can only be activated through the experienced, nondeprived (ND) eye, and responses to the deprived (D) eye are greatly reduced (2, 5, 6). Anatomical studies based on transneuronal transport of radioactive tracers injected into one eye of kittens monocularly deprived from eye-opening past the end of the critical period have demonstrated that cortical domains devoted to the D eye undergo a substantial shrinkage while those of the ND eye expand (5, 7). This finding suggests an anatomical basis for the functional shift of ocular dominance. The physiological effects of MD are detected after only 2 to 3 days of deprivation (8–13), and the magnitude of the deprivation effect is nearly as great after a week of deprivation as after months. Such plasticity has been thought to take place

too rapidly to be accounted for by anatomical changes; functional bases, such as inhibition of the input or a physiological down-regulation of the efficacy of existing synapses from the D eye, have been suggested (9, 14–16). In this view, the anatomical modifications produced by a brief period of MD would be evident only at the molecular level and would not be detectable in the light microscope.

To study the processes that couple physiological regulation to anatomical changes, we evaluated and compared geniculocortical axonal arbors in animals monocularly deprived for either 4 weeks (long-term) or 6

to 7 days (short-term) during the critical period (17). Genulocortical afferents were anterogradely filled from the lateral geniculate nucleus (LGN) with the phaseolus lectin (PHA-L) (18). The tracer was injected in lamina A of the right and left LGNs, allowing the analysis, in the two hemispheres of the same animal, of geniculocortical afferents serving the D or ND eye. Labeled geniculocortical projections were visualized with standard immunohistochemical techniques (18). A total of 38 arbors were reconstructed in three dimensions (19–21).

Following long-term MD, the labeled afferents serving the D eye showed a reduction in the complexity of the terminal arborization while the afferents serving the ND eye expanded (Fig. 1), consistent with the pattern seen in previous transneuronal labeling experiments (5). Surprisingly, even in the short-term MD experiments, geniculocortical arbors serving the occluded eye were similarly affected (Fig. 2). This result suggests that the physiological ocular dominance shift of cortical neurons produced by short-term MD is associated, at least after 6 days of MD, with a broad restructuring of the terminal arborization and not only with a functional suppression of the weaker input.

To quantify these observations, we measured and compared two parameters of the axonal arborization of LGN neurons in layer 4: (i) the total length of the arborization, obtained from the three-dimensional data, as a measure of growth; and (ii) the total number of branch points, as a measure of arbor complexity. The mean values of




Fig. 1. Coronal view of geniculocortical arbors reconstructed in kittens in which one eye had been occluded for 33 days. The terminal arborization of the deprived (D) eye shows a dramatic reduction in complexity as compared to that of the nondeprived (ND) eye. Cortical layers 3 and 4 are indicated by arrowheads.




Fig. 2. Coronal view of geniculocortical arbors reconstructed in kittens in which one eye had been occluded for 6 to 7 days. The borders of cortical layers 3 and 4 are indicated by arrowheads.

W. M. Keck Foundation Center for Integrative Neuroscience, Department of Physiology, Box 0444, University of California, San Francisco, CA 94143.